The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
Abstract
OBJECTIVES: To improve the bioavailability of antitubercular drugs (ATDs) as well as to assess the feasibility of administering ATDs via the respiratory route, this study reports the formulation of three frontline ATDs, i.e. rifampicin, isoniazid and pyrazinamide encapsulated in poly (DL-lactide-co-glycolide) nanoparticles suitable for nebulization. METHODS: Drug-loaded nanoparticles were prepared by the multiple emulsion technique, vacuum-dried and nebulized to guinea pigs. The formulation was evaluated with respect to the pharmacokinetics of each drug and its chemotherapeutic potential in Mycobacterium tuberculosis infected guinea pigs. RESULTS: The aerosolized particles exhibited a mass median aerodynamic diameter of 1.88 +/- 0.11 microm, favourable for bronchoalveolar lung delivery. A single nebulization to guinea pigs resulted in sustained therapeutic drug levels in the plasma for 6-8 days and in the lungs for up to 11 days. The elimination half-life and mean residence time of the drugs were significantly prolonged compared to when the parent drugs were administered orally, resulting in an enhanced relative bioavailability (compared to oral administration) for encapsulated drugs (12.7-, 32.8- and 14.7-fold for rifampicin, isoniazid and pyrazinamide, respectively). The absolute bioavailability [compared to intravenous (i.v.) administration] was also increased by 6.5-, 19.1- and 13.4-fold for rifampicin, isoniazid and pyrazinamide, respectively. On nebulization of nanoparticles containing drugs to M. tuberculosis infected guinea pigs at every 10th day, no tubercle bacilli could be detected in the lung after five doses of treatment whereas 46 daily doses of orally administered drug were required to obtain an equivalent therapeutic benefit. CONCLUSIONS: Nebulization of nanoparticles-based ATDs forms a sound basis for improving drug bioavailability and reducing the dosing frequency for better management of pulmonary tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dhuley, J. N. (1999) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.1999.tb01347.x · Cited by 4
RetractedBiodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 990
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.004 · Cited by 814
Infectious Diseases: Considerations for the 21st Century
Fauci, A. S. (2001) · Clinical Infectious Diseases · doi:10.1086/319235 · Cited by 443
Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration
Jacobs, C., & Müller, R. H. (2002) · Pharmaceutical Research · doi:10.1023/a:1014276917363 · Cited by 439
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201
Dailey, L. A., Schmehl, T., Gessler, T., Wittmar, M., Grimminger, F., Seeger, W., & Kissel, T. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00370-x · Cited by 180
Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification
Lamprecht, A., Ubrich, N., Hombreiro Pérez, M., Lehr, C.-M., Hoffman, M., & Maincent, P. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00107-6 · Cited by 169
Deol, P., & Khuller, G. K. (1997) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(96)00088-8 · Cited by 160
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Drug delivery systems: An updated review
Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.96920 · Cited by 1,671
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-613pp · Cited by 745
Nanoparticles for drug delivery to the lungs
Sung, J. C., Pulliam, B. L., & Edwards, D. A. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2007.09.005 · Cited by 643
Nanomedicine in pulmonary delivery
Mansour, H., Haemosu, & Wu, X. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s4937 · Cited by 485
Targeted delivery of nanoparticles for the treatment of lung diseases
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.006 · Cited by 440
“[71,72] studied different routes of administration for the treatment of tuberculosis.”
BackgroundNanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections
Abed, N., & Couvreur, P. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.02.009 · Cited by 358
Current approaches to enhance CNS delivery of drugs across the brain barriers
Lu, C.-T., Zhao, Y.-Z., Wong, H. L., Cai, J., Peng, L., & Tian, X.-Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61288 · Cited by 350
Photodynamic therapy in the control of oral biofilms
Soukos, N. S., & Goodson, J. M. (2011) · Periodontology 2000 · doi:10.1111/j.1600-0757.2010.00346.x · Cited by 342
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318
“1ml of sterile isotonic saline (standardized procedure in our laboratory in lieu of the absence of aerosol infection facilities).(17) The animals were maintained in biological safety cabinets.”
MethodInfluentialSelf-citationInhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis
Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314
Self-citationPulmonary applications and toxicity of engineered nanoparticles
Card, J. W., Zeldin, D. C., Bonner, J. C., & Nestmann, E. R. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00041.2008 · Cited by 307
Nanoparticle formulations in pulmonary drug delivery
Bailey, M. M., & Berkland, C. J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20140 · Cited by 302
Delivery of antibiotics with polymeric particles
Xiong, M.-H., Bao, Y., Yang, X.-Z., Zhu, Y.-H., & Wang, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.002 · Cited by 302
Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System
Kingsley, J. D., Dou, H., Morehead, J., Rabinow, B., Gendelman, H. E., & Destache, C. J. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9032-4 · Cited by 280
Biodegradable polymeric nanocarriers for pulmonary drug delivery
Rytting, E., Nguyen, J., Wang, X., & Kissel, T. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.6.629 · Cited by 266
New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
Sosnik, A., Carcaboso, Á. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.023 · Cited by 264
Magnetic core-shell nanoparticles for drug delivery by nebulization
Verma, N. K., Crosbie-Staunton, K., Satti, A., Gallagher, S., Ryan, K. B., Doody, T., McAtamney, C., MacLoughlin, R., Galvin, P., Burke, C. S., et al. (2013) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-11-1 · Cited by 260
Dry powder inhalers for pulmonary drug delivery
Frijlink, H. W., & De Boer, A. H. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.67 · Cited by 259
Nanomedicine for respiratory diseases
Pison, U., Welte, T., Giersig, M., & Groneberg, D. A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.068 · Cited by 255
In Vitro Structural and Functional Evaluation of Gold Nanoparticles Conjugated Antibiotics
Saha, B., Bhattacharya, J., Mukherjee, A., Ghosh, A., Santra, C., Dasgupta, A. K., & Karmakar, P. (2007) · Nanoscale Research Letters · doi:10.1007/s11671-007-9104-2 · Cited by 255
Toxicology and Drug Delivery by Cucurbit[n]uril Type Molecular Containers
Hettiarachchi, G., Nguyen, D., Wu, J., Lucas, D., Ma, D., Isaacs, L., & Briken, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010514 · Cited by 254
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., & Sarmento, B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.020 · Cited by 245
Pulmonary drug delivery systems for tuberculosis treatment
Pham, D.-D., Fattal, E., & Tsapis, N. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.12.009 · Cited by 185
The formulation of nanomedicines for treating tuberculosis
Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123
Sharma, A., Pandey, R., Sharma, S., & Khuller, G. K. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.07.010 · Cited by 111
Self-citationNanoparticle-based therapy for respiratory diseases
SILVA, A. L. D., SANTOS, R. S., XISTO, D. G., ALONSO, S. D. V., MORALES, M. M., & ROCCO, P. R. M. (2013) · Anais da Academia Brasileira de Ciências · doi:10.1590/s0001-37652013005000018 · Cited by 42
Chimote, G., & Banerjee, R. (2009) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31959 · Cited by 41
RTG-loaded nanomicelles (CS–VES–NAC) for oral anti-HIV drug delivery
Hu, L., Wu, J., Li, Z., Bu, M., Qiao, S., & Wang, H. (2016) · RSC Advances · doi:10.1039/c6ra09662j · Cited by 4
Metadata
- Authors
- Pandey, R.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11-12
- Volume
- 52
- Issue
- 6
- Pages
- 981-986
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2129055298
- Cited by
- 388
- References
- 22
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.